NCT00502307 - A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma | Biotech Hunter

Enrollment

272

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Tivozanib (AV-951)

solid oral dosage form taken daily for three weeks per one month cycle

DRUG

Placebo comparator

solid oral capsule containing excipients dosed daily for three weeks per month

Trial Locations (26)

125284

Moscow

129128

Moscow

632004

Vellore

Unknown

Kolkata

Mumbai

New Delhi

Pune

Astrakhan

Kazan'

Moscow

Obninsk

Pyatigorsk

Rostove-on-Don

Saint Petersburg

Sochi

Tomsk

Ufa

Veliky Novgorod

Yoshkar-Ola

Cherkassy

Dnipro

Donetsk

Kharkiv

Lviv

Uzhhorod

Zaporizzhya